PIK3CA and breast cancer: Although PIK3CA and CDH1 mutations are the therapy target and the risk factor in BC separately (33, 34), survival analysis suggested weak relevance between PIK3CA or CDH1 mutations and the clinical outcomes in both TCGA and METABRIC datasets (Figures S4A, B).